
Sign up to save your podcasts
Or


Why do GLP-1 therapies transform some patients—and barely move the needle in others? 🧬💉
A recent Nature study (~28,000 participants) identifies GLP1R and GIPR variants linked to both weight loss efficacy and GI side effects.
📊 Signal: modest for weight loss, stronger for tolerability
🧠Insight: genetics + clinical factors explain ~25% variability
🚀 Implication: early steps toward precision obesity therapeutics
The future may not be "one drug fits all," but one genome, one strategy.
By Dr RR Baliga, MD, MBA5
66 ratings
Why do GLP-1 therapies transform some patients—and barely move the needle in others? 🧬💉
A recent Nature study (~28,000 participants) identifies GLP1R and GIPR variants linked to both weight loss efficacy and GI side effects.
📊 Signal: modest for weight loss, stronger for tolerability
🧠Insight: genetics + clinical factors explain ~25% variability
🚀 Implication: early steps toward precision obesity therapeutics
The future may not be "one drug fits all," but one genome, one strategy.

895 Listeners

3,360 Listeners

19,524 Listeners